Claims

1. A pharmaceutical product comprising a solid unit dosage form which comprises citalopram, wherein the solid unit dosage form is prepared by a process comprising a step wherein citalopram base or a pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient is roller compacted.

2. The pharmaceutical product of claim 1, wherein the citalopram base or pharmaceutically accceptable salt thereof is essentially undiluted at the roller compacting step.

3. The pharmaceutical product of claim 1, wherein the citalopram base or pharmaceutically acceptable salt thereof is mixed with essentially all the excipients at the roller compacting step.

4. The pharmaceutical product of claim 1, wherein the solid unit dosage form comprises 2-60% w/w active ingredient calculated as citalopram base.

5. The pharmaceutical product of claim 1, wherein the solid unit dosage form comprises 10-40% w/w active ingredient calculated as citalopram base.

6. The pharmaceutical product of claim 1, wherein the solid unit dosage form comprises 15-25% w/w active ingredient calculated as citalopram.

7. The pharmaceutical product of claim 1, wherein the granulate after compaction has a median particle size of at least 40 μm.

8. The pharmaceutical product of claim 1, wherein the granulate after compaction has a median particle size of 40- 250 μm.

9. The pharmaceutical product of claim 1, wherein the granulate after compaction has a median particle size of 45 - 200 μm.

10. The pharmaceutical product of claim 1, wherein the granulate after compaction has a median particle size of 50 - 180 μm.

11. The pharmaceutical product of any of claims 1-10, comprising citalopram hydrobromide or citalopram hydrochloride.